Corporation announced further advancements in its ongoing strategy to bring translational discoveries to patient care by ...

Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet ...

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, ...

The stock's fall snapped a three-day winning streak.

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of Bio-Techne (NasdaqGS:TECH) with a Outperform ...

Argus analyst David Toung lowered the firm’s price target on Bio-Techne (TECH) to $90 from $95 and keeps a Buy rating on the shares after its ...

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

Equities research analysts at Evercore ISI assumed coverage on shares of Bio-Techne (NASDAQ:TECH – Get Free Report) in a ...

MINNEAPOLIS, March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands ...